Programable Albumin-Hitchhiking Nanobodies Enhance the Delivery of STING Agonists to Potentiate Cancer Immunotherapy.

MLA

Wilson, John, et al. “Programable Albumin-Hitchhiking Nanobodies Enhance the Delivery of STING Agonists to Potentiate Cancer Immunotherapy.” Research Square, May 2024. EBSCOhost, https://doi.org/10.21203/rs.3.rs-3243545/v1.

APA

Wilson, J., Kimmel, B., Arora, K., Chada, N., Bharti, V., Kwiatkowski, A., Finklestein, J., Hanna, A., Arner, E., Sheehy, T., Pastora, L., Yang, J., Pagendarm, H., Stone, P., Taylor, B., Hubert, L., Gibson-Corley, K., May, J., McLean, J., … Hargrove-Wiley, E. (2024). Programable Albumin-Hitchhiking Nanobodies Enhance the Delivery of STING Agonists to Potentiate Cancer Immunotherapy. Research Square. https://doi.org/10.21203/rs.3.rs-3243545/v1

Chicago

Wilson, John, Blaise Kimmel, Karan Arora, Neil Chada, Vijaya Bharti, Alexander Kwiatkowski, Jonah Finklestein, et al. 2024. “Programable Albumin-Hitchhiking Nanobodies Enhance the Delivery of STING Agonists to Potentiate Cancer Immunotherapy.” Research Square, May. doi:10.21203/rs.3.rs-3243545/v1.